Drug intelligence / Profile preview

ABCL386

Development stage: Preclinical
Lead developer: AbCellera Biologics
Modality: Antibody-Based Therapeutics

Overview

ABCL386 is an investigational, potential first-in-class antibody-based biologic being developed by AbCellera Biologics for the treatment of undisclosed oncology indications. Nominated as a development candidate in the fourth quarter of 2025, the drug is currently undergoing Investigational New Drug (IND) and Clinical Trial Application (CTA)-enabling activities. AbCellera intends to submit regulatory filings and commence Phase 1/2 clinical trials in patients in 2027. The specific molecular target and mechanism of action have not yet been publicly disclosed by the developer.

Beyond the preview

Go deeper on ABCL386.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABCL386.

Explore the full profile